Edward Tenthoff analyst PIPER SANDLER

Currently out of the existing stock ratings of Edward Tenthoff, 816 are a BUY (91.38%), 70 are a HOLD (7.84%), 7 are a SELL (0.78%).

Edward Tenthoff

Work Performance Price Targets & Ratings Chart

Analyst Edward Tenthoff, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 53.78% that have a potential upside of 55.28% achieved within 356 days.

Edward Tenthoff’s has documented 1,700 price targets and ratings displayed on 97 stocks. The coverage is on Healthcare, Technology, Industrials, Energy, Consumer Cyclical, Basic Materials sectors.

Most recent stock forecast was given on MRNA, Moderna at 26-Jun-2026.

Wall Street Analyst Edward Tenthoff

Analyst best performing recommendations are on SKYE (SKYE BIOSCIENCE, COMMON STOCK).
The best stock recommendation documented was for AVEO (AVEO PHARMACEUTICALS) at 6/23/2017. The price target of $20 was fulfilled within 4 days with a profit of $7.5 (60%) receiving and performance score of 150.

Average potential price target upside

AGLE Aeglea Bio Therapeutics ALNY Alnylam Pharmaceuticals ALPN Alpine Immune Sciences APVO Aptevo Therapeutics ARAV Aravive ARGX argenx NV ADR ARVN Arvinas ARWR Arrowhead Pharmaceuticals AVEO AVEO Pharmaceuticals BCYC Bicycle Therapeutics Ltd CCXI ChemoCentryx CRSP Crispr Therapeutics AG CYTK Cytokinetics DYN Dyne Therapeutics  EXEL Exelixis FATE Fate Therapeutics GMDA Gamida Cell Ltd INFI Infinity Pharmaceuticals IPSC Century Therapeutics KLDO Kaleido Biosciences KYMR Kymera Therapeutics MCRB Seres Therapeutics MRKR Marker Therapeutics MRNA Moderna NVAX Novavax NXTC NextCure  OPK Opko Health PSTX Poseida Therapeutics PTI Proteostasis Therapeutics RAPT RAPT Therapeutics STRO Sutro Biopharma SYBX Synlogic SYRS Syros Pharmaceuticals TPST Tempest Therapeutics TTPH Tetraphase Pharmaceuticals XNCR Xencor LIFE aTyr Pharma SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals ARNA Arena Pharmaceuticals ASLN Aslan Pharmaceuticals Ltd ADR CBAY Cymabay Therapeu CHMA Chiasma EIGR Eiger Biopharmaceuticals ELOX Eloxx Pharmaceuticals FULC Fulcrum Therapeutics GNCA Genocea Biosciences JNCE Jounce Therapeutics LEGN Legend Biotech Corp LRMR Larimar Therapeutics MIST Milestone Pharmaceuticals FSTX FStar Therapeutics GLUE Monte Rosa Therapeutics KRON Kronos Bio  OMGA Omega Therapeutics PNT POINT Biopharma Global PRTC PureTech Health PLC SBPH Spring Bank Pharmaceuticals VCEL Vericel Corp Ord XOMA XOMA Corp ZFGN Zafgen APTO Aptose Biosciences GILD Gilead Sciences REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma GRTS Gritstone Oncology XFOR X4 Pharmaceuticals CFRX ContraFect Corp IDRA Idera Pharmaceuticals KDMN Kadmon Holdings MTNB Matinas BioPharma Holdings ONCS OncoSec Medical MESO Mesoblast Ltd GRTX Galera Therapeutics CUE Cue Biopharma SKYE Skye Bioscience, Common Stock ARRY Array Technologies  CAMP CalAmp Corp CAPR Capricor Therapeutics IGMS IGM Biosciences INO Inovio Pharmaceuticals ACRV Acrivon Therapeutics, Common Stock AL Air Lease AP Ampco-Pittsburgh AR Antero Resources Corp AS Amer Sports CRDF Cardiff Oncology CTMX CytomX Therapeutics GM General Motors Company IBRX Immunitybio KRO Kronos Worldwide LENZ LENZ Therapeutics ONVO Organovo Holdings SY So-Young International AGL agilon health KPTI Karyopharm Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 16-Aug-2023

$12

$-15.6 (-56.52%)

$12.5

2 years 8 months 4 days ago
(13-Nov-2023)

2/2 (100%)

$1.82 (17.88%)

10

Buy Since 25-Jul-2023

$23

$-4.6 (-16.67%)

$22.5

2 years 8 months 24 days ago
(23-Oct-2023)

2/2 (100%)

$10.59 (85.33%)

120

Hold Since 03-Mar-2023

3 years 4 months 14 days ago
(03-Mar-2023)

0/3 (0%)

$161.25 (75.44%)

Buy Since 27-Oct-2022

$25

3 years 8 months 20 days ago
(27-Oct-2022)

1/4 (25%)

$6.75 (36.99%)

151

Buy Since 04-Feb-2022

4 years 1 months 14 days ago
(03-Jun-2022)

3/3 (100%)

$-30.5 (-77.22%)

161

Show more analysts

Please expand the browser size to see the chart

Which stock is Edward Tenthoff is most bullish on?

Potential upside of $56.65 has been obtained for CRSP (CRISPR THERAPEUTICS AG)

Which stock is Edward Tenthoff is most reserved on?

Potential downside of -$0.5 has been obtained for FULC (FULCRUM THERAPEUTICS)

What Year was the first public recommendation made by Edward Tenthoff?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?